Kornimate/medical-research-clean huggingface dataset:
cognitive rehabilitation through personalized virtual reality and paper-and-pencil interventions in the alcohol use disorder treatment.

Conditions: Alcohol Use Disorder (AUD)

Summary: cognitive dysfunction is one of the different consequences of excessive alcohol consumption, affecting many domains associated with prefrontal and temporal lobes, such as attention, verbal fluency, and memory. this study will explore the clinical impact of two cognitive rehabilitation tools to promote cognitive improvements of aud individuals.

excessive consumption of alcohol affects many functions associated with the prefrontal and temporal lobes, including different executive functions, memory, and complex motor control. among several treatments, the transtheoretical model, a multidisciplinary approach, is one of the most standardized. however, it lacks effective and innovative cognitive rehabilitation tools. in this study, two cognitive rehabilitation tools, already clinically validated for stroke patients, will be implemented to promote cognitive recovery of alcohol use disorder (aud) individuals under treatment in the alcoholic rehabilitation center s. ricardo pampuri from casa de saúde s. joão de deus (madeira, portugal). within a randomized controlled trial with 60 participants, this study intend to assess and compare the clinical effectiveness of both a paper-and-pencil tasks training and content equivalent virtual reality (vr) simulation of activities of daily living with time-matched standard treatment.

Eligibility criteria:
inclusion criteria: * inpatients of centro de alcoologia ricardo pampuri (with alcohol use disorder diagnosis) * education (able to read and write) * standard neuropharmacological protocol exclusion criteria: * abuse of other substances * neurological and psychiatric pathology (present or past) * severe depressive symptoms as assessed by the beck depression inventory * visual problems that can affect the performance of the tasks (hemianopsy, diplopia)

Keywords: alcohol use disorder cognitive rehabilitation virtual reality paper-and-pencil tasks
phase 2 study of quizartinib in participants with acute myeloid leukemia (aml) flt3 internal tandem duplication (flt3/itd) mutation

Conditions: Leukemia, Myeloid, Acute

Summary: this is a phase 2, multi-center, open-label study to evaluate the efficacy, safety and pharmacokinetics of quizartinib monotherapy in japanese subjects with flt3-itd positive refractory or relapsed acute myeloid leukemia.


Eligibility criteria:
inclusion criteria: * aml patients in first relapse or refractory after all prior therapy * presence of the flt3-itd activating mutation in bone marrow or peripheral blood * eastern cooperative oncology group (ecog) performance status (ps) of 0 to 2 exclusion criteria: * diagnosis of acute promyelocytic leukemia * aml secondary to prior chemotherapy for other neoplasms. * persistent, clinically significant \> grade 1 non-hematologic toxicity from prior aml therapy * prior treatment with a flt3 targeted therapy * active infection not well controlled by antibacterial, antifungal and/or antiviral therapy

Keywords: flt3-itd positive refractory or relapsed acute myeloid leukemia hematology malignancy developmental phase ii
open-label extension study of intravitreal aflibercept injection (iai; eylea®; bay86-5321) in neovascular ("wet") age-related macular degeneration (amd)

Conditions: Neovascular Age-related Macular Degeneration

Summary: the primary objective is to assess long-term safety and tolerability of intravitreal aflibercept injection (iai; eylea®; bay86-5321) in patients with neovascular amd.

the dose evaluated in this study, intravitreal aflibercept injection (iai; eylea®; bay86-5321) 2mg, will be the higher of the 2 dose strengths evaluated in parent study vgft-od-0605 (nct00509795) and is the dose level administered in study vgft-od-0702 (nct00527423), a long-term open-label extension study. for these reasons, this dose has been selected for this extension study. participants will be seen in the clinic for quarterly visits starting with day 1 to assess safety. study drug will be administered on an as-needed basis at the discretion of the investigator with a minimum allowed interval of every 4 weeks and a maximum allowed interval of every 12 weeks. this study will assess the frequency that re-treatment is needed and the effect of continued intravitreal aflibercept injection (iai; eylea®; bay86-5321) treatment on bcva.

Eligibility criteria:
inclusion criteria: * participation in study vgft-od-0605 through week 96. * in the opinion of the investigator, the study eye has neovascular amd and may continue to require treatment. exclusion criteria: * presence of any condition that would jeopardize the patient's participation in this study. * females who are pregnant, breastfeeding, or of childbearing potential, unwilling to practice adequate contraception throughout the study.

Keywords: eyes neovascular macular degeneration retina amd vegf trap-eye best corrected visual acuity
improvements in dynamic contrast-enhanced mr angiography and perfusion and non-contrast mri

Conditions: Prostate Neoplasm

Summary: this study evaluates if technical improvements in mri can be used to provide improved performance contrast-enhanced mri as used for angiography and perfusion as well as in non-contrast mri.

primary objective: i. to study how a variety of technological approaches in mri can be used to provide improved performance contrast-enhanced mr imaging as used for angiography and perfusion as well as in mr image acquisition without the use of contrast material. outline: this is an observational study. participants undergo a non-contrast mri on study and may optionally undergo a second non-contrast mri on study. participants may also undergo blood sample collection on study.

Eligibility criteria:
inclusion criteria: * adults exclusion criteria: * standard exclusion criteria for clinical mri; e.g. cardiac pacemaker, claustrophobia, an implanted device that has been determined to be mr conditional at 1.5t but not at 3t, anticipated considerable susceptibility artifact from hip prosthesis, etc.
the effect of ai-assisted ceeg diagnosis on the administration of antiseizure medication in neonatal seizures

Conditions: Neonatal Seizure

Summary: this is a prospective randomised clinical trial study to test an artificial intelligence (ai)-assisted continuous electroencephalogram(ceeg) diagnostic tool for optimizing the administration of antiseizure medication (asm) in neonatal intensive care units(nicus).

the occurrence of neonatal seizures may be the first, and perhaps the only, clinical sign of a central nervous system disorder in the newborn infant. the promoted treatment of seizures can limit the secondary injury to the brain and positively affect the infant's long-term neurological development. however, the current antiseizure medication (asm) are both overused and underused. studies indicated that early automated seizure detection tool had a high diagnostic accuracy of neonatal seizures. however, there is little evidence that early automated seizure detection tool could the optimize the administration of asm and improved the neurological outcomes in neonatal seizures. therefore, the primary study aim is to investigate whether the utility of ai assisted ceeg diagnostic tool could optimize the administration of asm in nicus. this project will enroll the neonates with suspected or high risk of seizures who will receive at least 72 hours ceeg monitoring during hospitalization. all the ceeg monitoring methodology is standardized across recruiting hospitals. the intervention will be an artificial intelligence (ai)-assisted continues electroencephalogram (ceeg) diagnostic tool. the individuals were randomly allocated to one of the two groups using a predetermined randomisation sequence and block randomisation generator (block of 4). the group 1 will be monitored with ceeg and the ceeg recording will be assessed by neonatologists with ai assisted ceeg diagnostic tool in real time during ceeg monitoring. the group 2 will be monitored with ceeg and the ceeg recording will be assessed by neonatologists when as routine during ceeg monitoring. both groups will follow the standard clinical protocols for asm administration of the recruiting hospitals the reference standard is the electrographic seizures interpreted by 3 clinicians who had attended the uniformly training program and were certified by the chinese anti-epilepsy association. these 3 clinicians are blinded to the group allocation.

Eligibility criteria:
inclusion criteria: * postnatal age \< or = 28 days; * ceeg monitoring at least 24hours monitoring; * suspected seizures； * abnormal movement; * brain infarction； * risk of intracranial hemorrhage; * abnormality of brain mri or ultrasound; * hypoxic-ischemic encephalopathy or suspected hypoxic-ischemic encephalopathy; * central nervous system (cns) or systemic infections; * suspected genetic diseases or positive genetic diagnoses; exclusion criteria: * the neonates with head scalp defect, scalp hematoma, edema and other contraindications which are not suitable for ceeg monitoring during hospitalization.
wearable devices faciliate the management of ami patients

Conditions: Acute Myocardial Infarction

Summary: the study will explore the use of wearable technology to consistently monitor patients with acute myocardial infarction (ami) receiving primary percutaneous coronary intervention (pci). parameters such as heart rate, sleep time, physical activity, and blood pressure will be collected and analyzed to characterize the patients and predict clinical outcomes.

the aim of this study is to explore in-hospital patient management and predict clinical outcomes in ami patients receiving primary pci through wearable technology (e.g., smart watches and wristband devices). the investigators expect to involve patients diagnosed with ami, including st-elevation myocardial infarction (stemi) and non-st-elevation myocardial infarction (nstemi), who are admitted to the cardiac cardiac intensive care unit (cicu) after primary pci. with written consent, eligible participants will be consistently monitored by a wearable device during the cicu stay, in addition to a conventional monitoring system. vital signs including heart rate (beats/minute), oxygen saturation (%) blood pressure (mmhg), and other crucial parameters such as sleep patterns will be recorded. the collected data will be analyzed using ai-assisted and machine learning techniques, integrated with other clinical data to construct models that support risk stratification, guide clinical decision-making, improve the quality of nursing care, and predict long-term prognosis for these patients. serial follow-ups (6-month, annual, and long-term) will be performed, and important information such as cardiac function assessed by echocardiography, the incidence of major adverse cardiovascular events, and life qualities will be collected for each follow-up.

Eligibility criteria:
inclusion criteria: * aged 18-75 years old * diagnosed with stemi or nstemi (acc/aha guidelines) * half male and half female * undergo cag and pci treatment; * written informed consent. exclusion criteria: * people under the age of 18 years old; * patients who are pregnant/breastfeeding; * patients who are allergic to the metallic or plastic components of the wearable devices
rsa-measured in vivo migration and micromotion in the depuy tri-lock, corail and deltamotion hip replacement components

Conditions: Hip Osteoarthritis

Summary: hip replacements are being performed on an increasingly active population, who are likely to wear their implants out prematurely. new hip replacements have been devised to minimise the risk of failure. depuy rsa rct is a randomised controlled trial designed to compare the performance of two established types of hip replacements using corail and tri-lock stems along with deltamotion acetabular component. the primary objective of the trial is to compare the long term stability of these two devices.to do this, the study will use an advanced 3d xray technique to detect migration of the components at 3 years. the study will also measure micromotion of corail, tri-lock and deltamotion components, patient reported outcome measures and change in bone density.this study is being conducted at a single site, at the nuffield orthopaedic centre, oxford.


Eligibility criteria:
inclusion criteria: * women aged between 18 and 65 years and men aged between 18 and 70 years. * participant is willing and able to give informed consent for participation in the study. * diagnosed with hip osteoarthritis. * able (in the investigators opinion) and willing to comply with all study requirements. * willing to allow his or her general practitioner and consultant, if appropriate, to be notified of participation in the study. exclusion criteria: * any patients with an inflammatory arthropathy, osteoporosis or deformities of the proximal femur. * patients who have significant co-morbidities that would make follow-up difficult or uncomfortable. * any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
effects of antioxidant dentifrice on gingivitis

Conditions: Gingivitis

Summary: the purpose of this study is to investigate the effect of a dentifrice containing l-ascorbic acid 2-phosphate magnesium salt on gingival inflammation, gingival bleeding and gingival redness.


Eligibility criteria:
inclusion criteria: * age between ≥ 20 and \< 65 y with at least 16 permanent teeth. * gingival inflammation or mean baseline gi ≥ 0.5 without severe periodontal disease enough to require professional therapy. * written informed consent to participate. exclusion criteria: * taking medications that could influence periodontal tissue health, such as antimicrobials and antihypertensives within 1 month before starting the trial. * use of orthodontic appliances. * pregnancy or planning to become pregnant during the trial period. * previous participation in any other clinical trial. * inability of patient to understand the study purpose and/or study protocols. * judged unsuitable by investigators for other reasons.

Keywords: gingivitis antioxidant dentifrice ascorbic acid derivative l ascorbic acid 2 phosphate magnesium salt
efficacy of rifaximin in treatment of cirrhotic gastroesophageal variceal bleeding

Conditions: Cirrhosis; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage

Summary: the purpose of the study is to evaluate the efficacy of rifaximin in the treatment of cirrhotic gastroesophageal variceal bleeding.

gastroesophageal variceal bleeding is the most common and life-threatening condition in patients with portal hypertension, which are susceptibility to bacterial infection. however, the prophylaxis use of antibiotics remained uncertain and lack of high level evidences. the purpose of the study is to evaluate the efficacy of rifaximin in the treatment of cirrhotic gastroesophageal variceal bleeding.

Eligibility criteria:
inclusion criteria: * 18 y.o. ≤age≤75 y.o.; * cirrhotic gastroesophageal variceal bleeding underwent endoscopic treatment (include esophageal varices ligation, endoscopic injection sclerosis and gastric n-butyl-cyanoacrylate injection). exclusion criteria: * age \ 75 y.o.; * never had the variceal bleeding episode before; * do not have endoscopic treatment; * combined with other malignant tumor (not exclude patients with hepatocellular carcinoma who don't not need treatment at the moment); * known infection after endoscopic treatment (fever, microbial cultures positive, et al.) * massive ascites or combined with other high risk factor that require prophylaxis use of antibiotics. * acute variceal bleeding within 5 days. * use of other antibiotics in the past 2 weeks; * refuse to participate
how do alpha oscillations shape the perception of pain? - an eeg-based neurofeedback study

Conditions: Experimental Pain in Healthy Human Subjects

Summary: pain is closely linked to alpha oscillations (8 -13 hz) which are thought to represent a supra-modal, top-down mediated gating mechanism that shapes sensory processing. consequently, alpha oscillations might also shape the cerebral processing of nociceptive input and eventually the perception of pain. to test this mechanistic hypothesis, the investigators designed a sham-controlled and double-blind electroencephalography (eeg)-based neurofeedback study. in a short-term neurofeedback training protocol, healthy participants will learn to up- and downregulate somatosensory alpha oscillations using attention. subsequently, the investigators will investigate how this manipulation impacts experimental pain applied during neurofeedback. using bayesian statistics and mediation analysis, the investigators will test whether alpha oscillations mediate attention effects on pain perception. this approach promises causal insights into the role of alpha oscillations in shaping pain, and thereby extends previous correlative evidence. beyond, it can aid the development of novel, non-invasive modulatory treatment approaches for chronic pain, which are urgently needed. the prosed study protocol has been granted in-principle acceptance from plos biology and the corresponding registration can be found at the osf online repository \[www.osf.io/qbkj2\].


Eligibility criteria:
inclusion criteria: * aged 18-45 years * right-handedness (laterality quotient \> 60 on the edinburgh handedness inventory) * good command of german * written informed consent * attendance at both sessions and compliance with instructions throughout the experiment exclusion criteria: * pregnancy * neurological or psychiatric diseases (e.g., epilepsy, stroke, depression, anxiety disorders) * severe general illnesses (e.g., tumors, diabetes) * skin diseases (e.g., dermatitis, psoriasis or eczema) * current or recurrent pain * regular intake of medication (aside from contraception, thyroidal, and antiallergic medication) * surgical procedures involving the head or spinal cord * side-effects following previous thermal stimulation * contact to a person with a sars-cov-2 infection within the last 2 weeks * current symptoms of a cold or flu

Keywords: pain neurofeedback alpha neural oscillations attention brain registered report
treating pregnancy related insomnia with music

Conditions: Pregnancy Related; Sleep Disturbance; Insomnia

Summary: this study aims to examine the effects of 4 weeks music listening at bedtime on sleep quality during the third trimester of pregnancy.

50-60% of pregnant women suffer from insomnia during pregnancy. pregnancy-related insomnia is often neglected due to a lack of suitable and safe treatments. this study aims to evaluate the effectiveness of music compared to sleep hygiene on sleep quality in a population of first-time pregnant women in the final stages of pregnancy. a post pregnancy follow-up will be completed to test if potential effects of the treatment might last into early motherhood (1-3 months postpartum).

Eligibility criteria:
inclusion criteria: * female, aged 18 years or above, pregnant non-mothers * have a sufficient level of danish (verbal) to understand and respond to the questions and task instructions * pregnant women will be enrolled in gestation week 29. exclusion criteria: * postnatal depression, i.e. a score of 12 or above on the epds questionnaire * comorbid psychiatric disorder (i.e. epilepsy and depression) * using sleep medication * working more than two night shifts per week * history of sleep disorders

Keywords: music sleep insomnia non-pharmaceutic sleep disturbances
a study of penpulimab and anlotinib plus nab-paclitaxel and gemcitabine for metastatic pancreatic cancer.

Conditions: Pancreatic Neoplasms

Summary: it is a trial to assess the efficacy and safety of penpulimab and anlotinib in combination with nab-paclitaxel plus gemcitabine as first-line therapy in patients (pts) with metastatic pancreatic cancer.


Eligibility criteria:
inclusion criteria: * ages ≥18 years，ecog ≤ 2，estimated survival time \> 3 months * histologically or cytologically confirmed metastatic pancreatic adenocarcinoma * based on response evaluation criteria in solid tumors (recist1.1), there should be at least one measurable lesion * patients have never received systematical anti-cancer therapy * laboratory examination meets the following requirements:white blood cell (wbc) ≥3.0×109/l; absolute neutrophil count (anc) ≥1.5×109/l; hemoglobin (hb) ≥90g/l; platelet count(plt) ≥75×109/l; total bilirubin (tbil) ≤1.5× normal upper limit (uln); alanine aminotransferase (alt) and aspartate aminotransferase (ast)≤2.5×uln, if accompanied by liver metastasis, alt and ast≤5×uln; serum creatinine (cr) ≤1×uln or creatinine clearance (ccr)≥50ml/min; * doppler ultrasound evaluation: left ventricular ejection fraction (lvef) \> 50% * patients of childbearing age should take appropriate protective measures before enrollment and during the trial * volunteer to join the study, sign the informed consent, have good compliance, and cooperate with follow-up * ability to follow the study protocol and follow-up procedures. exclusion criteria: * patients have ever received any systematical anti-cancer therapy in the past * patients who participated in other clinical trials in the past 4 weeks * according to the investigator, patients who surgically available or potentially treatable(patients who voluntarily give up surgical treatment can be enrolled after evaluation by the investigator) * patients with moderate ascites requiring drainage * patients with cns metastases and/or carcinomatous meningitis * patients with history of other primary malignancies except: 1) complete remission before enrollment for at least 2 years and requiring no additional treatment during the study period; 2) adequately treated non-melanoma skin cancer or lentiform malignancy with no evidence of disease recurrence; 3) adequately treated carcinoma in situ with no evidence of disease recurrence; * patients with autoimmune disease or immune deficiency who are treated with immunosuppressive drugs * patients with bleeding tendency. * pregnant or lactating women. * drug abuse, clinical or psychological or social factors that impact informed consent or the conduct of the study * patients who may be allergic to pd-1 monoclonal antibody, anlotinib, albumin-bound paclitaxel and gemcitabine